Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%
Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_4

Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China

NCT04762472
unknownearly_phase_1

Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers

NCT05381207
unknownphase_2

Investigation the Effect of Montelukast in COVID-19

NCT04718285

Clinical Trials (3)

Showing 3 of 3 trials
NCT04762472Phase 4

Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China

Unknown
NCT05381207Early Phase 1

Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers

Unknown
NCT04718285Phase 2

Investigation the Effect of Montelukast in COVID-19

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3